Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Capital Employed (2018 - 2025)

VYNE Therapeutics (VYNE) has disclosed Return on Capital Employed for 7 consecutive years, with 0.95% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Return on Capital Employed fell 55.0% year-over-year to 0.95%, compared with a TTM value of 0.95% through Jun 2025, down 55.0%, and an annual FY2025 reading of 0.64%, changed 0.0% over the prior year.
  • Return on Capital Employed was 0.95% for Q2 2025 at VYNE Therapeutics, down from 0.92% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.35% in Q1 2024 and bottomed at 2.23% in Q1 2021.
  • Average Return on Capital Employed over 4 years is 0.94%, with a median of 0.77% recorded in 2024.
  • The sharpest move saw Return on Capital Employed surged 250bps in 2021, then tumbled -57bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.7% in 2021, then increased by 18bps to 0.57% in 2023, then tumbled by -34bps to 0.77% in 2024, then fell by -24bps to 0.95% in 2025.
  • Business Quant data shows Return on Capital Employed for VYNE at 0.95% in Q2 2025, 0.92% in Q1 2025, and 0.77% in Q4 2024.